BC
REGN icon

Boxer Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Boxer Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-135,000
Closed -$65.9M – 67
2020
Q1 		$65.9M Buy
+135,000
New +$55.7M 4.49% 6
2016
Q3 		– Sell
-20,000
Closed -$6.99M – 30
2016
Q2 		$6.99M Buy
+20,000
New +$7.7M 6.19% 5

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Boxer Capital's REGN Position: Q2 2020 in Review

Boxer Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 135,000 shares — an estimated $65.9M sold.

Boxer Capital first reported a position in REGN in Q2 2016 and held it in 2 quarters. The position peaked at $65.9M in Q1 2020. 933 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Boxer Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Boxer Capital sold 135,000 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $65.9M.
  • Boxer Capital first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Boxer Capital's Regeneron Pharmaceuticals position peaked at $65.9M in Q1 2020.
  • 933 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Boxer Capital's 13F filing for Q2 2020, filed 14 Aug 2020.